Pfizer-BioNTech Vaccine Trials Show Encouraging Results in Children
Pfizer-BioNTech says that clinical trials in kids aged 12-15 showed the vaccine to be safe and effective. The data haven’t been fully released and analyzed by independent scientists, but the companies say the vaccine may be even more effective in young adolescents than in adults. Officials knowledgeable on the vaccine development process predict that middle school and high school students could start receiving the vaccine in time for Fall classes.
Full Story: New York Times